Immunotherapy breakthrough led by UCLA researcher now approved as standard of care for advanced melanoma

A first-of-its-kind (anti-PD-1) immunotherapy has been approved by the U.S. Food & Drug Administration as first-line treatment for metastatic melanoma, allowing greater access to this therapy for...